Science Entrepreneur Club’s Post

Looking forward to that discussion (with some additional thoughts on the question „who will do the earlier medtech investing in the future to generate these later stage cos ?)

Biotech Week Boston 2024 is just around the corner, taking place from September 23-26 at the Hynes Convention and Exhibition Center in Boston. We are thrilled to announce that Life Science Nation (LSN) will be hosting the RESI Boston 2024 Conference on September 25 at The Westin Copley Place, just a short 10-minute walk from the Biotech Week venue. Following the in-person conference, a two-day virtual partnering event will be held on September 26-27. RESI Boston will bring together over 300 early-stage life science investors and licensing partners, as well as more than 300 early-stage life science companies. Whether you are a CEO seeking funding, an investor hunting for cutting-edge technologies, or a service provider looking for business opportunities, RESI Boston is an event you cannot afford to miss. 📅 Register by July 5 to take advantage of the Super Early Bird Rates and save $500! Plus, use discount code MKTYZ to receive an additional $100 off. 🔗 RESI Boston Registration: https://cvent.me/ZN4gvn Don't miss out on this incredible opportunity to connect, network, and propel your business forward. See you in Boston! #BiotechWeekBoston #RESIBoston #LifeScience #Investors #Startups #Networking #Innovation #Biotech #Healthcare #Pharma #Entrepreneurship #BostonEvents #BusinessGrowth #Partnering #Investment #RESI #LSN #LifeScienceNation

Finding the right investors is essential for Medtech startups to ensure long-term success, and family offices can be a valuable source of capital. But what are the unique considerations and strategies when approaching these investors? In our upcoming #LSIEurope24 panel, "Raising Capital from Family Offices," we’ll hear from perspectives from around the table including family office investors, venture investors, and innovators. They will share their insights on the process, challenges, and nuances of raising capital from family office investors. Featured Panelists: • Alexei Mlodinow (Moderator), Former CEO & Co-Founder, SIA (Acquired by Integra LifeSciences) • Tyler Wanke, Investor, Wanke Family Office • John Slump, Co-Founder, CEO, & President, Atraverse Medical, Inc. • Pablo Prieto, Managing Director, CG Health Ventures Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with nearly 1,000 global Medtech and Healthtech leaders in Sintra, Portugal.

€7.7M in Non-Dilutive Funding to Accelerate Growth Across Our Portfolio. Four of our portfolio companies have been awarded grants through PARP's competitive "SMART Path" program. Only 200 startups were selected out of more than 2,700 that applied, and we are proud to have our companies among them! Molecule.one: €3.3M Smarter Diagnostics: €2.7M Aether Biomedical: €1.4M Codejet: €0.4M These grants are equity-free funding, in addition to private investment rounds. This significant boost will further empower our companies to accelerate their growth. cc: Polska Agencja Rozwoju Przedsiębiorczości, Polski Fundusz Rozwoju S.A. (PFR), PFR Ventures

Navigating the Biotech Surge 🚀 Boston's biotech landscape in 2024 is a testament to innovation! From startup incubators to industry giants, we're seeing a remarkable convergence of talent and technology. 💡🧬 Despite global economic tremors, biotech has stood resilient, cueing in a record-breaking number of IPOs this year. The key? Collaboration. The tight-knit community here fosters partnerships that are pushing medical boundaries, with a remarkable spotlight on personalized medicine. It's incredible to witness how these synergies are speeding up drug development pipelines - something that once took decades is now unfolding in years, if not months. And let's talk investment 💲💹 - Boston biotech is a hotbed for venture capital, with funding rounds catapulting startups onto the global stage. But it's not just about the money; it's about the purpose-driven zeal of entrepreneurs set on solving complex health challenges. As someone embedded in this ecosystem, I can't help but marvel at our pace. Are we on the cusp of the next big breakthrough? How do you see Boston's biotech innovation shaping our future? Share your thoughts! 🤝🌐 #BiotechBoom #BostonInnovation #HealthcareFutures

Excited for this upcoming event, especially with Nucleate Germany being involved. It’s truly a unique opportunity for startups, investors, and industry leaders to tackle key funding challenges in life sciences. If you’re interested in learning more about Nucleate and would like to connect, feel free to reach out during the event. Looking forward to a day of insightful discussions and meaningful conversations! #biotech #investing #startups #lifesciences

News from 4PM Ventures We are pleased to announce that the willingness to cooperate with us, to jointly invest in startups that will come to the https://lnkd.in/enNVcpHT, to develop the ecosystem is supported by more and more partners and venture funds. Meet the Polish fund Impera Alfa ASI Sp. z o.o. and join our lab. Startups with a Healthtech focus have time to apply by June 8 to participate in the laboratory. And another important offer for private investors and venture funds: we know that you have investments in healthtech startups with the focus of our laboratory. We also know that many of them are developing more slowly than you would like, or maybe there is a question about pivot. Send startups to our laboratory, we are sure that many of them will develop faster and solve problems that hinder their development. More info here 4PM Ventures #vc; #health; #healthtech; #4PM; #medicine; #medicaldevices; #rehabtech

Can’t wait to meet you all today at EMERGE 2050 and PrecisionMed Exhibition & Summit to speak about the Effective Strategies for Increasing Valuation and Achieving Successful Exits in #Healthtech, #Medtech and #Biotech. Join us on the Panel Discussion: Finance and governance the Business Pillars of Healthcare Startups, with industry leaders Steve Gardner, Willem Baralt, and Joe Hawayek.

A little self-serving as an IP attorney but can’t disagree with Howard Levin’s take on the role of IP in seeking VC funding. In the past few weeks, I have heard first hand about a VC pulling out of a deal because a medtech company got sued for patent infringement, another medtech startup received a letter of infringement and freaked out about what that means, another medtech company was granted a motion to dismiss a patent lawsuit, not to mention current and prospective clients wanting to file IP. My take on IP in medtech is that it is critically important and can get really expensive. The best way for startups to build an effective and robust patent portfolio is to first delay public disclosures for as long as possible to extend the clock to file (hence delaying spend), pursuing omnibus patent applications (to reduce the cost per invention), being strategic about what features to protect, being aware of each jurisdiction’s requirements around patenting, and being strategic around conducting landscape assessments to identify patent threats from competitors.

Europe has become a vibrant hub for health technology 😍 The digital health sector has seen some shifts, with funding and deal volume seeing noticeable reductions in 2023. Investors are showing their support for startups venturing into novel treatment approaches and addressing nonclinical workflow challenges. 💰 In 2023, biotech & pharma emerged as the winner of sector trends. 🔬 Let's explore which investors played a pivotal role in shaping early-stage (Seed - Series A) health-tech deals in Europe in 2023: 1- EQT Group HQ: Amsterdam Health-tech / Life Science deals: 197 2- HTGF | High-Tech Gründerfonds HQ: Bonn Health-tech / Life Science deals: 175 3- Sofinnova Partners HQ: Paris Health-tech / Life Science deals: 121 4- Calm/Storm HQ: Vienna Health-tech / Life Science deals: 76 5- NLC Health Ventures HQ: Amsterdam Health-tech / Life Science deals: 72 6- Mercia Ventures HQ: Henley in Arden Health-tech / Life Science deals: 68 Take a look at the full list of TOP 25 VC funds by following this link 👉 https://lnkd.in/gPEuV5Ju #healthtech #digitalhealth #venturecapital